Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of "Moderate Buy" by Analysts

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $35.71.

A number of equities research analysts have commented on the company. Wedbush reduced their price objective on Xencor from $36.00 to $34.00 and set an "outperform" rating for the company in a research note on Wednesday, February 28th. Royal Bank of Canada restated an "outperform" rating and issued a $32.00 target price on shares of Xencor in a report on Wednesday, February 28th. BMO Capital Markets dropped their target price on Xencor from $38.00 to $34.00 and set an "outperform" rating on the stock in a report on Wednesday, February 28th. Piper Sandler restated a "neutral" rating and issued a $24.00 target price (down previously from $37.00) on shares of Xencor in a report on Wednesday, February 28th. Finally, Mizuho dropped their target price on Xencor from $59.00 to $50.00 and set a "buy" rating on the stock in a report on Monday, January 22nd.

Insider Activity at Xencor

In other news, VP John R. Desjarlais sold 1,280 shares of the business's stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $23.50, for a total value of $30,080.00. Following the transaction, the vice president now directly owns 186,433 shares in the company, valued at $4,381,175.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Xencor news, VP John R. Desjarlais sold 1,280 shares of the business's stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $23.50, for a total transaction of $30,080.00. Following the sale, the vice president now directly owns 186,433 shares of the company's stock, valued at $4,381,175.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bassil I. Dahiyat sold 12,528 shares of the business's stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $23.43, for a total value of $293,531.04. Following the sale, the chief executive officer now directly owns 300,097 shares in the company, valued at $7,031,272.71. The disclosure for this sale can be found here. Over the last three months, insiders have sold 101,351 shares of company stock worth $2,152,417. Corporate insiders own 4.97% of the company's stock.

Institutional Trading of Xencor

A number of large investors have recently modified their holdings of XNCR. CWM LLC increased its position in shares of Xencor by 498.7% during the fourth quarter. CWM LLC now owns 1,377 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 1,147 shares in the last quarter. Parallel Advisors LLC increased its position in shares of Xencor by 303.9% during the fourth quarter. Parallel Advisors LLC now owns 1,349 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 1,015 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Xencor by 95.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,548 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 756 shares during the period. BluePath Capital Management LLC acquired a new position in shares of Xencor in the 3rd quarter valued at $31,000. Finally, Signaturefd LLC increased its position in shares of Xencor by 367.7% in the 4th quarter. Signaturefd LLC now owns 1,464 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 1,151 shares during the period.

Xencor Stock Performance

Shares of XNCR stock traded up $0.05 during trading on Tuesday, reaching $21.55. 481,722 shares of the company's stock were exchanged, compared to its average volume of 705,962. The company has a quick ratio of 7.36, a current ratio of 7.36 and a debt-to-equity ratio of 0.02. The firm's fifty day moving average price is $22.12 and its 200-day moving average price is $20.40. Xencor has a twelve month low of $16.49 and a twelve month high of $30.21. The stock has a market capitalization of $1.32 billion, a PE ratio of -10.26 and a beta of 0.76.

Xencor (NASDAQ:XNCR - Get Free Report) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.36 by ($0.67). The company had revenue of $44.70 million for the quarter, compared to analyst estimates of $77.63 million. Xencor had a negative return on equity of 18.67% and a negative net margin of 74.90%. The business's revenue for the quarter was up 106.9% compared to the same quarter last year. During the same period last year, the company posted ($0.20) earnings per share. As a group, sell-side analysts anticipate that Xencor will post -3.24 EPS for the current year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.